Surrogacy of one-year survival for overall survival in advanced hepatocellular carcinoma

Jin, Yuzhi; Ren, Hui; Yue, Qianhua; Wu, Wei; Liu, Chuan; Guo, Yixuan; Zhao, Peng

doi:10.1186/s12885-024-12000-7

BMC Cancer

Table 1 Characteristics of eligible clinical trials included in the study

From: Surrogacy of one-year survival for overall survival in advanced hepatocellular carcinoma

Number	Trial^a	Year of publication	Treatment setting	Trial phase	Arms	Sample size	ORR by RECIST	Median PFS (months)	Median OS (months)	One-year survival rate (%)
1	NCT00108953	2010	1st	II	Doxorubicin Plus Sorafenib	47	0.04	6.0	13.7	50.47
1					Doxorubicin Plus Placebo	49	0.02	2.7	6.5	28.57
2	CELESTIAL / NCT01908426	2018	2nd or 3rd	III	Cabozantinib	470	0.04	5.2	10.2	44.71
2					placebo	237	0.004	1.9	8.0	31.56
3	NCT01507168	2016	≥ 2nd	II	codrituzumab	125	0.008	2.6	8.7	35.56
3					placebo	60	0	1.5	10	28.19
4	NCT01287585	2018	≥ 2nd	III	ADI-PEG 20	424	0.008	2.6	7.8	31.70
4					placebo	211	0.028	2.6	7.4	35.54
5	NCT01015833	2019	1^st	III	Doxorubicin Plus Sorafenib	180	0.1	4.0	9.3	43.59
5					Sorafenib	176	0.054	3.7	9.4	37.14
6	Shukui Qin	2021	1^st	II-III	Donafenib	328	0.046	3.7	12.1	51.26
6					Sorafenib	331	0.027	3.6	10.3	47.18
7	RESORCE / NCT01774344	2017	2^nd	III	Regorafenib	379	0.07	3.4	10.6	40.86
7					placebo	194	0.03	1.5	7.8	28.44
8	NCT01009593	2014	1^st	III	Linifanib	514	0.101	5.4	9.1	48.91
8					Sorafenib	521	0.061	4.0	9.8	41.04
9	KEYNOTE-240 / NCT02702401	2019	2^nd	III	Pembrolizumab	278	0.183	3.8	13.9	57.86
9					placebo	135	0.044	2.8	10.6	46.94
10	NCT00492752	2009	1^st	III	Sorafenib	150	0.033	2.8	6.5	21.98
10					placebo	76	0.013	1.4	4.2	11.29
11	NCT00699374	2013	1^st	III	Sunitinib	530	0.066	3.6	7.9	35.92
11					Sorafenib	544	0.061	3.0	10.2	43.80
12	IMbrave150 / NCT03434379	2020	1^st	III	Atezolizumab + Bevacizumab	336	0.298	6.9	19.2	60.69
12					Sorafenib	165	0.114	4.3	13.4	52.79
13	Ann-Lii Cheng	2016	1^st	II	Dovitinib	82	0.06	4.11	8.07	28.73
13					Sorafenib	83	0.101	4.18	8.56	42.98
14	REACH-2 / NCT02435433	2019	2^nd	III	Ramucirumab	197	0.05	2.8	8.5	38.79
14					Placebo	95	0.01	1.6	7.3	28.15
15	REACH / NCT01140347	2015	2^nd	III	Ramucirumab	283	0.07	2.8	9.2	40.57
15					Placebo	282	0.0007	2.1	7.6	34.97
16	NCT02774187	2019	1^st	III	Sorafenib + HAIC	125	0.408	7.03	13.37	52.64
16					Sorafenib	122	0.025	2.6	7.13	17.99
17	UMIN000005703	2016	1^st	II	Sorafenib + HAIC	65	0.217	3.1	10.6	41.12
17					Sorafenib	41	0.073	2.8	8.7	33.33
18	NCT01075555	2019	1^st	III	Sorafenib + pravastatin	162	0.079	5.0	10.7	42.61
18					Sorafenib	161	0.112	4.4	10.5	48.96
19	NCT01210495	2015	2^nd	II	Axitinib + BSC	134	0.097	3.6	12.7	52.71
19					Placebo + BSC	68	0.029	1.9	9.7	37.48
20	REFLECT / NCT01761266	2018	1^st	III	Lenvatinib	478	0.188	7.4	13.6	53.61
20					Sorafenib	476	0.065	3.7	12.3	45.84
21	S-CUBE / JapicCTI-090920	2017	2^nd	III	S-1	222	0.05	2.6	11.1	45.19
21					placebo	111	0.009	1.4	11.2	44.35
22	NCT02029157	2020	2^nd or 3^rd	III	Tivantinib	134	0.052	2.8	10.3	39.63
22					placebo	61	0.098	2.3	8.5	32.32
23	NCT01214343	2018	1^st	III	Sorafenib + HAIC	102	0.36	4.8	11.8	48.10
23					Sorafenib	103	0.18	3.5	11.5	44.92
24	NCT02329860	2021	≥ 2^nd	III	Apatinib	261	0.11	4.5	8.7	35.98
24					Placebo	132	0.02	1.9	6.8	33.54
25	NCT00825955	2013	2^nd	III	Brivanib	263	0.12	4.2	9.4	38.88
25					Placebo	132	0.02	2.7	8.2	32.69
26	NCT00105443	2008	1^st	III	Sorafenib	299	0.02	5.5	10.7	41.39
26					Placebo	303	0.01	2.8	7.9	30.30
27	NCT01829035	2019	1^st	III	Sorafenib + cTACE	170	0.118	5.2	12.8	53.21
27					Sorafenib	169	0.059	3.6	10.8	44.62
28	NCT01755767	2018	2^nd	III	Tivantinib	226	0	2.1	8.4	38.29
28					Placebo	114	0	2.0	9.1	38.83
29	NCT02528643	2021	≥ 2^nd	II	Enzalutamide	110	0.018	2.23	7.75	28.45
29					Placebo	55	0	1.87	7.69	31.48
30	NCT03009461	2022	1^st	II	Sorafenib + HAIC	32	0.41	9.0	16.3	37.78
30					Sorafenib	32	0.03	2.5	6.5	14.29
31	CheckMate459 / NCT02576509	2022	1^st	III	Nivolumab	371	0.15	3.7	16.4	52.57
31					Sorafenib	372	0.07	3.8	14.7	54.89
32	NCT0901901	2015	1^st	III	Sorafenib + Erlotinib	362	0.066	3.2	9.5	39.12
32					Sorafenib + Placebo	358	0.039	4.0	8.5	40.65

^aEach trial can be identified with clinical trial registration number. For the trials without referring number, the first authors of the corresponding papers were listed

Back to article page

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com